绝经后妇女骨质疏松治疗进展

绝经后妇女骨质疏松主要是由于体内雌激素水平特别是雌二醇水平降低,属原发性骨质疏松症。随着社会老龄化的推进,骨质疏松症日益成为影响公众健康的重大问题。目前,绝经后妇女骨质疏松症的治疗以内服药为主。巴多昔芬代表着一类有前途的预防和治疗绝经后骨质疏松的新疗法,并可与共轭雌激素联合应用来治疗妇女相关的更年期症状。阿仑膦酸钠能够显著抑制骨吸收、增加骨密度、降低骨折风险。两者是预防和治疗绝经后骨质疏松症值得推荐的药物。护骨素蛋白含有380个氨基酸,是一种分泌型糖蛋白,这些信号及通路中的一些蛋白分子已作为骨质疏松治疗的新靶点。拮抗硬化蛋白的抗骨质疏松治疗具有良好的应用前景。维生素K、钙剂和维生素D也有很好的抗骨质疏松作用。

Advances in the treatment of postmenopausal osteoporosis

Postmenopausal osteoporosis is mainly due to the estrogen level in particular, estradiol levels, belong to primary osteoporosis. With the development of an aging society, osteoporosis is increasingly becoming the major problems affecting the public health. At present, the treatment of postmenopansal osteoporosis is for oral administration. Bazedoxifene is a kind of new medic.ine to prevent and treat postmenopausal osteoporosis, and can he applied to treat women symptoms of menopause eonjugated estrogen. Alendronate sodium can significantly inhibit bone absorption, increase bone density, reduce the risk of fractures. Bazedoxifene and Alendronate sodium are worth to be recommended to prevention and treatment of postmenopausal osteoporosis. Bone protein containing 380 amino acids, is a kind of secretion glycoprotein. Some of these signals and channel protein molecules have to be a new target for osteoporosis treatment. Anti-hardening protein is to be a good application prospect to treat osteoporosis. Vitamin K, calcium and vitamin D also have a vety good effect for anti-asteoporosis.